Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is neededMark S. Butler, Peter Beyer, Mical Paul et al.|Archive ouverte UNIGE (University of Geneva)|2022Cited by 221
Characterization of <i>Escherichia coli</i> NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3Richard A. Alm, Sushmita D. Lahiri|Journal of Antimicrobial Chemotherapy|2015Cited by 179
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsValeria Gigante, Alexandra Meagan Cameron, Richard A. Alm et al.|Antimicrobial Agents and Chemotherapy|2024Cited by 25
Highly potent quinoxalinediones inhibit α-hemolysin and ameliorate Staphylococcus aureus lung infectionsAditya Shekhar, Mark Brönstrup, Raffaella Di Lucrezia et al.|Cell Host & Microbe|2025Cited by 15